Gallant

Gallant is an animal health biotechnology company pioneering "ready-to-use" stem cell therapies for pets. Gallant's pipeline of off-the-shelf mesenchymal stem cell (MSC) therapies address conditions in dogs and cats—including feline chronic gingivostomatitis (FCGS), osteoarthritis, chronic kidney disease, and atopic dermatitis. Our first product, based on a proprietary uterine-derived stem cell platform, is on track for conditional FDA approval in 2026. Led by industry pioneers in veterinary regenerative medicine, Gallant combines science, purpose, and compassion to help pets live healthier, more vibrant lives.